Woodcock steps in at CDER as Galson departs

To help it implement new FDA reform legislation signed into law in September, the Bush administration has shaken up the leadership of the agency's drug center, whose flounderings over product safety more than anything else provoked passage of the FDA Amendments Act.

Drug center director Steven Galson was elevated to acting surgeon general.

His predecessor, FDA deputy commissioner and chief medical officer Janet Woodcock, who held the post for over a decade until 2005, has returned to the position on a temporary basis.

Galson's tenure was characterized by major public turbulence on the subordination of drug safety reviews to new drug-approval reviews, which he tried to reverse, the Vioxx and David Graham whistleblower controversy, and the uproar over the Plan B emergency contraceptive OTC switch.
FDA commissioner Andrew von Eschenbach told his employees in an e-mail that a national search for a permanent director for the drug center will begin “immediately.”

You must be a registered member of MMM to post a comment.
close

Next Article in Features


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters